BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously'
Tweet Send to a Friend
BofA Securities analyst Geoff Meacham reiterated an Underperform rating and $12.00 price target on Lyell Immunopharma (NASDAQ: LYEL)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
